<DOC>
	<DOCNO>NCT01547598</DOCNO>
	<brief_summary>This non-inferiority study assess safety efficacy LUMIGAN® RC ( bimatoprost ophthalmic solution 0.01 % ) versus DuoTrav® ( travoprost 0.004 % /timolol 0.5 % combination ophthalmic solution ) patient previously Travatan® Z ( travoprost ophthalmic solution 0.004 % ) monotherapy .</brief_summary>
	<brief_title>Safety Efficacy LUMIGAN® RC Versus DuoTrav® Patients Who Require Further Intraocular Pressure ( IOP ) Reduction</brief_title>
	<detailed_description />
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Cloprostenol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Open angle glaucoma ocular hypertension Best correct visual acuity 20/100 good eye Ocular surgery within 3 month , anticipate ocular surgery within 12 week Previous treatment LUMIGAN® RC DuoTrav® History LASIK , LASEK , RK PRK study eye ( ) Active ocular inflammation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>